Indian regulator CDSCO has granted marketing approval to Servier India for a novel brain-cancer drug — a development that could significantly augment therapeutic options for neuro-oncology patients. The green signal follows rigorous evaluation of clinical data and safety protocols. With rising incidence of brain tumours and limited existing treatments, this endorsement may not only improve patient outcomes, but also reshape India’s oncology-drug market, stimulating further innovation and competition in cancer therapy.